Ilari Lehtinen

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko‐Liisa Kellokumpu‐Lehtinen, Ulrika Harmenberg, Timo Joensuu et al. · The Lancet Oncology · 2013 · 208 citations

Medicine, Oncology, Urology +12

Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.

Petteri Hervonen, Heikki Joensuu, Timo Joensuu et al. · PubMed · 2012 · 24 citations

Medicine, Oncology, Pharmacology +15

Weekly paclitaxel--an effective treatment for advanced breast cancer.

Pirkko Kellokumpu‐Lehtinen, Tuija Tuunanen, R. Asola et al. · PubMed · 2013 · 23 citations

Medicine, Oncology, Pharmacology +17

A Phase I Study of an All-Oral Combination of Vinorelbine/Capecitabine in Patients with Metastatic Breast Cancer Previously Treated with Anthracyclines and/or Taxanes

Pirkko‐Liisa Kellokumpu‐Lehtinen, Kaisa Sunela, Ilari Lehtinen et al. · Clinical Breast Cancer · 2006 · 17 citations

Medicine, Oncology, Pharmacology +16